Since Coronavirus, there has been a lull in orthopedic IPOs', but the lull may be over next year.
First let's look back at the last 5 IPOs for reference and understand their terrible stock performance over the last 4 year (as of YE 2024)
May 2023 - Monogram Orthopaedics (80% drop in stock price, $13.50 to $2.66 to date)
October 2021 - Bone Biologics (99+% drop in stock price, $1099.20 to $1.12 to date)
April 2021 - Treace Medical Concepts (80% drop in stock price, $25.53 to $7.50 to date)
February 2021 - Bioventus (36% drop in stock price, $17.22 to $11.03 to date)
October 2020 - Paragon 28 (44% drop in stock price, $18.71 to $10.42 to date)
These numbers don't exactly make you want to pop the champagne, do they?
But the IPO market door may be opening up again in 2025 for a new crop of public orthos.
4 favorable dynamics influencing the IPO market for orthos:
1/ Strong Growth and Options. Strong companies like OSSIO doubling sales Y/Y with a non-permanent fixation monopoly are poised to be acquired, but may tap the public markets if an acquirer doesn't write a big enough check. Read - Where’s the implant? OSSIO ushers in natural bone fixation. First screw case and fresh fun...
